T. Rowe Price Associates’s Oric Pharmaceuticals ORIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28M | Buy |
2,762,915
+1,430,055
| +107% | +$14.5M | ﹤0.01% | 885 |
|
|
2025
Q1 | $7.44M | Buy |
1,332,860
+37,835
| +3% | +$211K | ﹤0.01% | 1166 |
|
|
2024
Q4 | $10.5M | Buy |
1,295,025
+180,140
| +16% | +$1.45M | ﹤0.01% | 1138 |
|
|
2024
Q3 | $11.4M | Sell |
1,114,885
-74,342
| -6% | -$762K | ﹤0.01% | 1119 |
|
|
2024
Q2 | $8.41M | Sell |
1,189,227
-377,509
| -24% | -$2.67M | ﹤0.01% | 1134 |
|
|
2024
Q1 | $21.5M | Buy |
1,566,736
+915,175
| +140% | +$12.6M | ﹤0.01% | 958 |
|
|
2023
Q4 | $6M | Buy |
651,561
+606,446
| +1,344% | +$5.58M | ﹤0.01% | 1169 |
|
|
2023
Q3 | $274K | Sell |
45,115
-17,949
| -28% | -$109K | ﹤0.01% | 2368 |
|
|
2023
Q2 | $490K | Buy |
63,064
+3,725
| +6% | +$28.9K | ﹤0.01% | 2139 |
|
|
2023
Q1 | $339K | Hold |
59,339
| – | – | ﹤0.01% | 2287 |
|
|
2022
Q4 | $350K | Hold |
59,339
| – | – | ﹤0.01% | 2314 |
|
|
2022
Q3 | $191K | Buy |
59,339
+6,900
| +13% | +$22.2K | ﹤0.01% | 2555 |
|
|
2022
Q2 | $235K | Sell |
52,439
-11,221
| -18% | -$50.3K | ﹤0.01% | 2529 |
|
|
2022
Q1 | $340K | Buy |
63,660
+15,891
| +33% | +$84.9K | ﹤0.01% | 2494 |
|
|
2021
Q4 | $702K | Buy |
+47,769
| New | +$702K | ﹤0.01% | 2215 |
|